Navigation Links
AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
Date:8/12/2008

All amounts are in U.S. dollars

QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the second quarter ended June 30, 2008.

Second Quarter 2008 Highlights

- Advancement of cetrorelix Phase 3 program in BPH;

- First efficacy trial: patient enrollment completed;

- Second efficacy trial: patient enrollment ongoing / completion

planned for third quarter of 2008 remains on target;

- Safety trial: first patient dosing initiated.

- Completion of sale of Quebec City building for $7.1 million.

Juergen Ernst, Chairman, Interim President and CEO at AEterna Zentaris commented, "During the quarter, we achieved our key objectives as our Phase 3 program in BPH with our lead compound cetrorelix met all recruitment goals and remains on track, with first results expected in the third quarter of 2009. Furthermore, we monetized our Quebec City building which provided additional non-dilutive funding. Over the next few months, we will focus on advancing our Phase 3 program in BPH with cetrorelix, while we endeavour to conclude additional non-dilutive transactions and strategic partnerships."

CONSOLIDATED RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2008

Consolidated sales and royalties increased to $8.2 million for the three-month period ended June 30, 2008, compared to $7.7 million for the same period in 2007. The increase in sales and royalties for the three-month period ended June 30, 2008 is related primarily to additional sales of Cetrotide(R), partly offset by the exclusion of sales from Impavi
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
2. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
3. AEterna Zentaris Sells Quebec City Building for $7.1 million
4. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
5. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
6. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
7. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
8. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
9. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
11. AEterna Zentaris Announces Changes to its Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 ... market research report is available ... Whole Exome Sequencing Market by ... Target Enrichment), by Services (Sequencing), ... by Application (Cancer, Monogenic disorders) ...
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
(Date:8/28/2014)... Fla. Exciting new work by a Florida State ... system that can take your temperature, emit white light, ... And, the molecule looks like a butterfly. , Biwu ... Biomedical Engineering in the FAMU-FSU College of Engineering, created ... but has continued to discover that his creation has ...
(Date:8/28/2014)... this month, a report was created by Colorado ... Force on the performance of vehicles using an eco-friendly, ... fuel made from mustard seeds, offered great potential as ... friendly future. In fact, every branch of the U.S. ... foreign oil over the next few years. They will ...
Breaking Biology Technology:Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... -- Theoretical work done at the Department of Energy,s ... understanding an unexpected magnetism between two dissimilar materials. ... special significance for the design of future electronic devices ... of ORNL,s Materials Science and Technology Division. The work ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) today ... September 30, 2010 after the market closes on Wednesday, November ... Chief Executive Officer, Kent Griffin, President, and Greg N. Lubushkin, ... 9:00 a.m. Pacific Time on Thursday, November 4, 2010 to ...
... England, Oct. 18 A 67-year-old female patient with ... tumor was small and it rode up and down ... doctors saw on their therapy system,s imaging equipment was ... Trust was able to utilize its Symmetry™ motion ...
Cached Biology Technology:ORNL theorist part of team that discovers unexpected magnetism 2BioMed Realty Trust to Report 2010 Third Quarter Results 2Clinicians Use Advanced Radiotherapy Imaging Techniques from Elekta to More Accurately Visualize Moving Tumors in Patients with Lung Cancer 2Clinicians Use Advanced Radiotherapy Imaging Techniques from Elekta to More Accurately Visualize Moving Tumors in Patients with Lung Cancer 3
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
(Date:8/29/2014)... twist them, fold them: modern materials that are light, ... as artificial skin or electronic paper. , Making such ... but a new way of working with copper nanowires ... , Previous success in the field of ultra-lightweight ... precious gold and silver nanowires. , By turning ...
(Date:8/28/2014)... that an expansion of marine protected areas is needed ... According to investigators from the Wildlife Conservation Society ... focused on saving the largest numbers of species, often ... and difficult-to-replace ecological functions. , Many vital ... species that also are food for millions of people. ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... , , , , ... Biometrics, Inc. (OTC Bulletin Board: PBME), a leading provider of ... entry into a Loan and Security Agreement with Terry M. Giles, ... In connection with, and as required by the Loan, on ...
... , , , , ... Reportlinker.com announces that a new market research report is available in ... Signature Verification Market , , ... worldwide markets for Dynamic Signature Verification in US$ Thousands. The market ...
... , WALL, N.J., Sept. 14 / PRNewswire-FirstCall / ... a leader in finger-based biometric identification and wireless public safety solutions, ... Advisor and Consultant to the company. Tom will play a major ... the government and commercial markets. , , (Logo: ...
Cached Biology News:Pacific Biometrics Completes $4 Million Debt Financing 2Pacific Biometrics Completes $4 Million Debt Financing 3Pacific Biometrics Completes $4 Million Debt Financing 4Pacific Biometrics Completes $4 Million Debt Financing 5Reportlinker Adds World Dynamic Signature Verification Market Report 2Reportlinker Adds World Dynamic Signature Verification Market Report 3Reportlinker Adds World Dynamic Signature Verification Market Report 4Reportlinker Adds World Dynamic Signature Verification Market Report 5Reportlinker Adds World Dynamic Signature Verification Market Report 6Reportlinker Adds World Dynamic Signature Verification Market Report 7Reportlinker Adds World Dynamic Signature Verification Market Report 8Reportlinker Adds World Dynamic Signature Verification Market Report 9BIO-key Retains Former Senior FBI Official as Strategic Advisor and Consultant 2BIO-key Retains Former Senior FBI Official as Strategic Advisor and Consultant 3BIO-key Retains Former Senior FBI Official as Strategic Advisor and Consultant 4
... was developed using a protein engineering approach that ... pocket of wild-type DNase I. These changes markedly ... The result is a versatile enzyme that has ... ability to maintain at least 50% of peak ...
Request Info...
MAb to Mouse MHC Class I H-2Kd...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
Biology Products: